Australia recommends the use of Pfizer's COVID-19 vaccine to people under 50
Reuters
Published Apr 08, 2021 19:37
CANBERRA, April 8 (Reuters) - Australia said on Thursday it now recommends the use of Pfizer (NYSE:PFE)'s PFE.N COVID-19 vaccine over that produced by AstraZeneca (NASDAQ:AZN) AZN.L . for people under the age of 50.
Europe's drug regulator on Wednesday found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all available evidence.
Australia's Chief Medical Officer Paul Kelly said that while the risk is extremely low, the country's experts have changed their advice for those at greatest risk.
Australia will continue to administer the AstraZeneca vaccine to people over 70.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.